Probiotic Use in Preterm Neonates: A Review and Bibliometric Analysis

Q4 Medicine

Acta Medica Bulgarica Pub Date : 2022-10-01 DOI:10.2478/amb-2022-0032

Y. Yordanov, Sen. Assistant Prof, MPharm Yordan Yordanov

{"title":"Probiotic Use in Preterm Neonates: A Review and Bibliometric Analysis","authors":"Y. Yordanov, Sen. Assistant Prof, MPharm Yordan Yordanov","doi":"10.2478/amb-2022-0032","DOIUrl":null,"url":null,"abstract":"Abstract Background: Necrotizing enterocolitis (NEC) is a major health burden in peterm neonates with mortality rates between 21% and 50%. Prophylaxis is of primary importance as early diagnosis is hindered by the lack of specific signs and laboratory markers. Although probiotics have been routinely used for NEC prophylaxis in neonatal intensive care units around the world, clinical trials provide contradictory data, which fuels an ongoing debate about their efficacy and safety. Aims: To perform a review and bibliometric analysis on available clinical trials and case reports data on the safety and efficacy of probiotics in preterm neonates and identify relevant publication trends and patterns. Methods: A bibliometric search for publications on the topic was performed in the Web of Science Core Collection database and the resulting records analyzed in bibliometrix package in R. Results: Trends in publication activity, historical direct citation network relationships and keyword co-ocurrences were discussed in the context of the most recent therapeutic recommendations. Conclusion: We took a round view of the potential drawbacks to probiotic use in preterm infants and their possible solutions.","PeriodicalId":35746,"journal":{"name":"Acta Medica Bulgarica","volume":"49 1","pages":"58 - 67"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Bulgarica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/amb-2022-0032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Background: Necrotizing enterocolitis (NEC) is a major health burden in peterm neonates with mortality rates between 21% and 50%. Prophylaxis is of primary importance as early diagnosis is hindered by the lack of specific signs and laboratory markers. Although probiotics have been routinely used for NEC prophylaxis in neonatal intensive care units around the world, clinical trials provide contradictory data, which fuels an ongoing debate about their efficacy and safety. Aims: To perform a review and bibliometric analysis on available clinical trials and case reports data on the safety and efficacy of probiotics in preterm neonates and identify relevant publication trends and patterns. Methods: A bibliometric search for publications on the topic was performed in the Web of Science Core Collection database and the resulting records analyzed in bibliometrix package in R. Results: Trends in publication activity, historical direct citation network relationships and keyword co-ocurrences were discussed in the context of the most recent therapeutic recommendations. Conclusion: We took a round view of the potential drawbacks to probiotic use in preterm infants and their possible solutions.

查看原文本刊更多论文

益生菌在早产儿中的应用：综述和文献计量分析

摘要背景：坏死性小肠结肠炎（NEC）是彼得姆新生儿的主要健康负担，死亡率在21%至50%之间。预防是最重要的，因为缺乏特定的体征和实验室标志物阻碍了早期诊断。尽管益生菌已在世界各地的新生儿重症监护室常规用于NEC预防，但临床试验提供了相互矛盾的数据，这引发了关于其疗效和安全性的持续争论。目的：对早产儿益生菌安全性和有效性的现有临床试验和病例报告数据进行综述和文献计量分析，并确定相关的出版趋势和模式。方法：在Web of Science核心收藏数据库中对该主题的出版物进行文献计量学搜索，并在R中的文献计量学包中分析结果记录。结论：我们全面了解了早产儿使用益生菌的潜在缺点及其可能的解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Medica Bulgarica Medicine-Medicine (all)

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

25 weeks

期刊介绍： About 30 years ago - in 1973, on the initiative of the Publishing House „Medicine and Physical Culture", namely its former director Mr. Traian Ivanov, the Ministry of Health set up and accepted to subsidize a new medical magazine that was to be published only in the English language and had to reflect the status and the achievements of the Bulgarian medical science. Thus the language barrier was overcome and stable relations were established with the international medical society, large libraries, and university centers. The famous internationally known scientist professor Assen A. Hadjiolov was elected edition-in-chief by the first editorial staff and the magazine was named Acta Medica Bulgarica.